2021 CMSC Annual Meeting

Tag: (6)Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology

Poster-Disease-modifying Therapy

Long-Term Effect of Siponimod on MRI Outcomes in Secondary Progressive Multiple Sclerosis: Analyses from the Expand Study up to 5 Years

Background: In the Phase 3 EXPAND core study, siponimod compared with placebo significantly reduced disability progression, cognitive...

Read More